An in vitro experiment by Sthoeger et al. revealed that the tolerogenic peptide hCDR1 could significantly reduce the expressions of IL-1β and TNF-α but increase the expressions of TGF-β and FOXP3 in the PBMCs of SjS patients, suggesting hCDR1 as a potential candidate treatment for SjS [205]. Here, IL1B is linked to Schwartz-Jampel syndrome.